Scholarlink

<p>Chronic obstructive pulmonary disease (COPD) is a major cause of mortality worldwide. A subset of patients with COPD have pulmonary type 2 inflammation, creating an opportunity for a personalised medicine approach in these individuals. Dupilumab and mepolizumab are approved for the management of COPD with type 2 inflammation, while ensifentrine is approved for use in a broader COPD population. Several more biological therapies (including tezepemulab, tozorakimab and itepekimab) remain under investigation for COPD with type 2 inflammation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Add dupilumab and mepolizumab to the toolbox for patients with chronic obstructive pulmonary disease and type 2 inflammation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月26日

查看全文
  • Thomas B. Burgess,
  • Connie Kang

摘要

Chronic obstructive pulmonary disease (COPD) is a major cause of mortality worldwide. A subset of patients with COPD have pulmonary type 2 inflammation, creating an opportunity for a personalised medicine approach in these individuals. Dupilumab and mepolizumab are approved for the management of COPD with type 2 inflammation, while ensifentrine is approved for use in a broader COPD population. Several more biological therapies (including tezepemulab, tozorakimab and itepekimab) remain under investigation for COPD with type 2 inflammation.